Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 6

Topotecan: An evolving option in the treatment of relapsed small cell lung cancer

Authors Jennifer Garst

Published 15 January 2008 Volume 2007:3(6) Pages 1087—1095

Jennifer Garst
Duke University Medical Center, Durham, North Carolina, USA
Abstract: The topoisomerase I inhibitor topotecan is the only single-agent therapy approved for the treatment of recurrent small cell lung cancer (SCLC). Many patients with recurrent SCLC may be predisposed to treatment-related adverse events because of the presence of comorbidities such as advanced age, renal impairment, or extensive prior therapy. In this setting, disease stabilization is considered a treatment benefit, and quality-of-life effects and toxicity profiles of treatments should be considered. The approved regimen of topotecan 1.5 mg/m2 on days 1 to 5 of a 21-day cycle is active and has generally mild nonhematologic toxicity and a well-established hematologic toxicity profile characterized by reversible, manageable, and noncumulative neutropenia. Alternative dosing and treatment schedules may lower the incidence of hematologic toxicities while maintaining antitumor efficacy in this patient population. Therefore, topotecan may provide physicians with an effective and versatile therapeutic option for the treatment of patients with relapsed SCLC.
Keywords: relapsed cancer, review, small cell lung cancer, topotecan

Download Article [PDF] 

Readers of this article also read:

Creating diagnostic scores using data-adaptive regression: An application to prediction of 30-day mortality among stroke victims in a rural hospital in India

Merrill D Birkner, SP Kalantri, Vaishali Solao, Priya Badam, Rajnish Joshi, Ashish Goel, Madhukar Pai, Alan E Hubbard

Therapeutics and Clinical Risk Management 2007, 3:475-484

Published Date: 15 July 2007

Editorial || FREE PAPER ||

Garry M Walsh

Therapeutics and Clinical Risk Management 2007, 3:211-212

Published Date: 15 May 2007

Oral mucositis induced by anticancer treatments: physiopathology and treatments

D’Hondt, Lionel, Lonchay, Christophe, André, Marc, Canon, Jean-Luc

Therapeutics and Clinical Risk Management 2006, 2:159-168

Published Date: 15 June 2006

Treatment of pruritic diseases with topical calcineurin inhibitors

Sonja Ständer, Funda Schürmeyer-Horst, Thomas A Luger, Elke Weisshaar

Therapeutics and Clinical Risk Management 2006, 2:213-218

Published Date: 15 June 2006

Renal cell carcinoma and the use of sorafenib

James MG Larkin, Tim Eisen

Therapeutics and Clinical Risk Management 2006, 2:87-98

Published Date: 15 March 2006